Regarding the efficacy and safety of potent P2Y12 inhibitor in elderly patients, a systematic review and meta-analysis reported that potent P2Y12 inhibitor increased the risk of bleeding compared to clopidogrel in elderly patients with acute coronary syndrome [20]. Here, P2RY12 is linked to acute coronary syndrome.